BrightPath Biotherapeutics Co's quarterly market cap
increased
from Mar. 2025 (円3,981.60 Mil) to Sep. 2025 (円7,797.37 Mil) and
increased
from Sep. 2025 (円7,797.37 Mil) to Mar. 2026 (円9,583.48 Mil).
BrightPath Biotherapeutics Co's annual market cap
declined
from Mar. 2024 (円4,598.17 Mil) to Mar. 2025 (円3,981.60 Mil) but then
increased
from Mar. 2025 (円3,981.60 Mil) to Mar. 2026 (円9,583.48 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BrightPath Biotherapeutics Co's Enterprise Value for Today is 円4,788.36 Mil.
BrightPath Biotherapeutics Co (TSE:4594) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BrightPath Biotherapeutics Co Market Cap Related Terms
BrightPath Biotherapeutics Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4594 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, BrightPath Biotherapeutics Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BrightPath Biotherapeutics Co Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's Market Cap distribution charts can be found below:
* The bar in red indicates where BrightPath Biotherapeutics Co's Market Cap falls into.
BrightPath Biotherapeutics Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BrightPath Biotherapeutics Co (TSE:4594) has a Market Cap of 円6,944.56 Mil as of Jul. 11, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BrightPath Biotherapeutics Co and its competitors. According to the industry distribution chart, BrightPath Biotherapeutics Co ranks #935 out of 1422 companies in the Biotechnology industry, placing it in the top 65.8%.
Is BrightPath Biotherapeutics Co's Market Cap too high?
BrightPath Biotherapeutics Co's current Market Cap is 円6,944.56 Mil. Based on the distribution chart, BrightPath Biotherapeutics Co ranks #935 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BrightPath Biotherapeutics Co ranks #935 out of 1422 companies for Market Cap. This places BrightPath Biotherapeutics Co in the lower half of its industry. The industry median Market Cap is 120.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 120.54, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BrightPath Biotherapeutics Co and its competitors. For the Biotechnology industry, the median Market Cap is 120.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BrightPath Biotherapeutics Co's current Market Cap is 円6,944.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co (TSE:4594) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.64, compared to a current price of 円50.00 — trading 977.6% above its estimated fair value. The current Market Cap is 円6,944.56 Mil. BrightPath Biotherapeutics Co's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current Market Cap is 円6,944.56 Mil as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BrightPath Biotherapeutics Co (TSE:4594) Overvalued in 2026?
Based on GuruFocus' analysis, BrightPath Biotherapeutics Co stock appears to be overvalued.
The current stock price of 円50.00 is trading 977.6% above its estimated GF Value™ of 円4.64.
GuruFocus considers BrightPath Biotherapeutics Co to be Significantly Overvalued.
Key valuation signals for TSE:4594:
Market Cap: 円6,944.56 Mil
GF Value™: 円4.64 vs. price of 円50.00 (977.6% above fair value)
No single metric tells the full story. See the TSE:4594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BrightPath Biotherapeutics Co Business Description
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
46GF Score
Get the complete analysis for TSE:4594
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4594 has been successfully added to your 
